Free Trial
NYSEAMERICAN:ASXC

Asensus Surgical (ASXC) Stock Price, News & Analysis

Asensus Surgical logo
$0.35 0.00 (0.00%)
As of 08/22/2024

About Asensus Surgical Stock (NYSEAMERICAN:ASXC)

Key Stats

Today's Range
$0.35
$0.35
50-Day Range
$0.35
$0.35
52-Week Range
$0.17
$0.40
Volume
N/A
Average Volume
2.03 million shs
Market Capitalization
$94.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.35
Consensus Rating
Hold

Company Overview

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

Receive ASXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Asensus Surgical and its competitors with MarketBeat's FREE daily newsletter.

ASXC Stock News Headlines

Warning: Massive IPO Predicted for May 14?
The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, May 14. And as Fortune has written, this IPO is “larger than any IPO valuation in history”…
See More Headlines

ASXC Stock Analysis - Frequently Asked Questions

Asensus Surgical's stock was trading at $0.3479 at the beginning of 2025. Since then, ASXC shares have increased by 0.0% and is now trading at $0.3479.
View the best growth stocks for 2025 here
.

Asensus Surgical, Inc. (NYSEAMERICAN:ASXC) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The company earned $2.57 million during the quarter, compared to the consensus estimate of $1.02 million. Asensus Surgical had a negative net margin of 902.25% and a negative trailing twelve-month return on equity of 184.10%.

Shares of ASXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Asensus Surgical investors own include Digital Turbine (APPS), CrowdStrike (CRWD), ChargePoint (CHPT), SoFi Technologies (SOFI) and Tesla (TSLA).

Company Calendar

Last Earnings
11/03/2021
Today
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NYSEAMERICAN:ASXC
CIK
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$0.35
High Stock Price Target
$0.35
Low Stock Price Target
$0.35
Potential Upside/Downside
+0.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-78,430,000.00
Net Margins
-902.25%
Pretax Margin
-899.16%

Debt

Sales & Book Value

Annual Sales
$8.58 million
Price / Cash Flow
N/A
Book Value
$0.13 per share
Price / Book
2.68

Miscellaneous

Free Float
264,516,000
Market Cap
$94.74 million
Optionable
Not Optionable
Beta
1.37
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NYSEAMERICAN:ASXC) was last updated on 5/12/2025 by MarketBeat.com Staff
From Our Partners